Calibre What Science Can Do

This website contains promotional content about AstraZeneca Medications. This website is intended for healthcare professionals involved in the Acute Coronary Syndrome care pathway, such as hospital specialists from cardiology and cardiology-related departments, including A&E and elderly care, as well as GPs with a specific interest in cardiology, nurses, pharmacists and payers with budget responsibilities in cardiology.

ACS insights

January 2018

The why, when and how of antiplatelet therapy in high-risk, post-myocardial infarction patients
Professor Christopher Gale

Professor Christopher Gale

Professor Christopher Gale is a professor of cardiovascular medicine at the Division of Epidemiology, University of Leeds. He is also an honorary consultant cardiologist and leads the Medical Research Council (MRC) Bioinformatics Centre’s Cardiovascular Epidemiology group. 

Professor Gale qualified in medicine at the London Hospital Medical College and obtained a BSc (Hons) in psychology. After working as a junior doctor at the Royal London Hospital andbecoming a member of the Royal College of Physicians, he became a MRC clinical training fellow and undertook a PhD in molecular biology at the University of Leeds. Professor Gale undertook specialty training in cardiology at the Leeds General Infirmary, where he was a NIHR academic clinical lecturer. He holds a Master’s in clinical education and a Master’s in statistical epidemiology. As a consultant cardiologist, he completed a 5-year NIHR Clinician Scientist Award to become an NIHR clinical trials fellow.

Professor Gale has published over 100 original research papers and is Deputy Editor of European Heart Journal – Quality of Care and Clinical Outcomes. Professor Gale is Chair of the research committee of the National Institute for Cardiovascular Outcomes Research. In addition to membership of the National Institute for Health and Care Excellence Indicator Advisory Committee, he is an oversight committee member of the European Society of Cardiology (ESC) EURObservational Research Programme and Secretary of the ESC Acute Cardiovascular Care Association.

The why, when and how of antiplatelet therapy in high-risk, post-myocardial infarction patients
Professor Philippe Gabriel Steg

Professor Philippe Gabriel Steg

Dr Philippe Gabriel Steg is a professor of cardiology at Université Paris Diderot and the National Heart and Lung Institute of Imperial College London. He is also an interventional cardiologist and Chief of the Cardiology Department at Hôpital Bichat, Assistance Publique-Hôpitaux de Paris. 

Dr Steg participates in the leadership of many trials in coronary artery disease and is currently Chair/co-Chair or principal investigator of several large clinical trials or registries such as ODYSSEY Outcomes, CLARIFY, THEMIS, REALITY, and SCORED. He is Chair of the FACT: French Alliance for Cardiovascular Clinical Trials academic research network, was co-Chair of the REACH registry and the GRACE registry publication committee, and participated in numerous data monitoring committees or clinical events committees.

Dr Steg is co-Coordinator of the Département Hospitalo-Universitaire FIRE affiliated with INSERM, Université Paris Diderot and Assistance Publique – Hôpitaux de Paris, and Coordinator of the iVASC research consortium. He has authored over 1,000 articles in international peer-reviewed journals, is Associate Editor for Circulation and on the editorial board for the European Heart Journal. He received the silver medal of the European Society of Cardiology (ESC) in 2011 and co-chaired the ESC task force in charge of the 2012 Guidelines for management of ST-segment elevation myocardial infarction.